Q-omics provides the consensus-scored IL10RA profile across patient tissues and cancer cell-line models. IL10RA expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, IL10RA is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, IL10RA RNA expression shows 23,066 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, KIRC, and LSCC as cancer lineages where IL10RA shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IL10RA — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IL10RA survival associations across molecular data types. IL10RA RNA expression shows survival associations in the most cancer types (21), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IL10RA RNA expression–survival associations across cancer types. High IL10RA expression shows unfavorable associations in THYM, but favorable associations in HNSC, SKCM, LUAD, CESC and PAAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for IL10RA RNA expression.
This table summarizes IL10RA tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for IL10RA. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IL10RA shows lower tumor expression in COAD, LUSC, LUAD and BLCA and higher tumor expression in KIRC and KIRP. The KIRC box plot shows higher IL10RA RNA expression in tumor versus normal tissue (log2 FC = +2.330, t-test p < 0.001).
This table shows molecular features associated with IL10RA in patient tissues and cancer cell lines. In patient samples, IL10RA shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, IL10RA RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
